𝗙𝗜𝗥𝗦𝗧 𝗔𝗟𝗭𝗛𝗘𝗜𝗠𝗘𝗥’𝗦 𝗕𝗟𝗢𝗢𝗗 𝗧𝗘𝗦𝗧:...

Discover how the first FDA-cleared blood test for Alzheimer’s disease, developed by Fujirebio,...

Overview of Alzheimer’s disease...

hello guys today's topic is ALZHEIMER"S DISEASE source
HomeVIDEOSRole in Alzheimer's,...

Role in Alzheimer’s, Use of TPE in Dementia, Indications for Therapeutic Plasma Exchange, Therapeuti



How would you approach a young adult with rapidly progressive cognitive-behavioral changes, marked memory impairment, spatial disorientation, and a strong family history of early dementia? What clinical, genetic, and biomarker findings would you integrate when counseling about investigational therapies and understanding the underlying etiology? Explore how advanced diagnostic evaluations can help unravel complex presentations in early-onset neurodegeneration.

VIDEO INFO
Category: Role in Alzheimer’s, Use of TPE in Dementia, Indications for Therapeutic Plasma Exchange, Therapeutic plasma exchange, Clinical Pathology
Difficulty: Expert – Expert level – For those seeking deep understanding
Question Type: Diagnosis – Identify conditions based on clinical presentation
Case Type: Complicated Condition

Explore more ways to learn on this and other topics by going to

QUESTION
A 24-year-old woman presents with 10 months of rapidly progressive cognitive-behavioral change. She reports misplacing items, spatial disorientation in large buildings, difficulty tracking multi-step tasks, and lapses in episodic memory. Early education and development were unremarkable. Family history is notable for her father s early dementia with myoclonus in his late 30s and death at 45; no neuropathology is available. She does not drink alcohol or use illicit drugs….

OPTIONS
A. Young-onset, biomarker-confirmed Alzheimer s disease due to a pathogenic PSEN1 mutation, with an amnestic-executive syndrome, posterior temporoparietal hypometabolism, and concordant amyloid and tau positivity.
B. Autosomal-dominant Alzheimer s disease due to APP duplication with cerebral amyloid angiopathy-predominant features, typically marked by microbleeds and lobar hemorrhage on MRI not seen here.
C. Logopenic variant primary progressive aphasia due to Alzheimer pathophysiology without autosomal-dominant mutation, despite the amnestic-predominant cognitive profile and PSEN1 pathogenicity.
D. Seronegative autoimmune limbic encephalitis causing predominant memory symptoms despite negative neuronal antibody panels, normal CSF indices, and Alzheimer-pattern molecular imaging.

CORRECT ANSWER
A. Young-onset, biomarker-confirmed Alzheimer s disease due to a pathogenic PSEN1 mutation, with an amnestic-executive syndrome, posterior temporoparietal hypometabolism, and concordant amyloid and tau positivity.

EXPLANATION
The totality of data points to autosomal-dominant Alzheimer s disease due to a pathogenic PSEN1 variant with fully concordant Alzheimer biomarkers. Clinically, the patient s amnestic-executive syndrome with topographical disorientation, impaired delayed recall, and posterior temporoparietal hypometabolism on FDG-PET is classic for Alzheimer s neurodegeneration. Molecularly, she is positive by a plasma pTau217/beta-amyloid 1-42 ratio run in a specialized laboratory, shows CSF Abeta42 low with elevated tau species, and has robust amyloid PET uptake in precuneus/posterior cingulate with supportive tau PET in temporal cortices. Genetically, a heterozygous PSEN1 pathogenic missense variant in a CLIA-certified lab with a family history of early dementia and myoclonus is diagnostic of young-onset autosomal-dominant Alzheimer s disease….

Further reading:

Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content.

—————————————————

Our cases and questions come from the quiz engine – multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations.

Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution – always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification.

Clinicians already rely on AI and online tools – myself included – so treat this content as an additional focused aid, not a replacement for proper medical education. Visit for more AI-supported resources and cases.

This material can not be treated as medical advice. May contain errors.

—————————————————

source

Continue reading

Genetic Mismatch Triples Severe Immune Risk

Cord blood transplants are known to tolerate genetic mismatches better than other donor sources. But one specific HLA pairing may sharply raise the risk of severe...

𝗙𝗜𝗥𝗦𝗧 𝗔𝗟𝗭𝗛𝗘𝗜𝗠𝗘𝗥’𝗦 𝗕𝗟𝗢𝗢𝗗 𝗧𝗘𝗦𝗧: 𝗚𝗔𝗠𝗘-𝗖𝗛𝗔𝗡𝗚𝗘𝗥 𝗜𝗡 𝗘𝗔𝗥𝗟𝗬 𝗗𝗜𝗔𝗚𝗡𝗢𝗦𝗜𝗦

Discover how the first FDA-cleared blood test for Alzheimer’s disease, developed by Fujirebio, is transforming early detection and diagnosis. This breakthrough not only simplifies screening but also brings huge economic and clinical value—especially amid shrinking federal funding for Alzheimer’s...

Can Organ Donation Happen After the Heart Stops?

Donation after circulatory death now accounts for nearly half of all deceased organ donors in the United States. Advances in preservation technology are helping make more...